Clinical Trials Logo

Exudative Macular Degeneration clinical trials

View clinical trials related to Exudative Macular Degeneration.

Filter by:
  • None
  • Page 1

NCT ID: NCT05093374 Recruiting - Clinical trials for Exudative Macular Degeneration

Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting

Start date: March 1, 2021
Phase: Phase 4
Study type: Interventional

The purpose of this study is to implement quantitative assessment tools for the treatment of active neovascular AMD patients in a real-world setting in order to provide advantages for both patients (treatment burden) and healthcare system (scheduling visits/treatments).

NCT ID: NCT04504123 Recruiting - Clinical trials for Wet Age-related Macular Degeneration

MMP-9 Inhibition for Recalcitrant Wet AMD

Start date: November 4, 2020
Phase: Phase 2
Study type: Interventional

Wet (or neovascular) form of age-related macular degeneration (wAMD) is the most common cause of blindness in the Western world. Currently, anti-vascular endothelial growth factor (VEGF) intravitreal injections (IVI) remain the standard-of-care treatment for wAMD. Previous studies show that about 90% of treated patients lose minimal visual function after 2 years of follow-up. There is still, a subset of 15% patients, incomplete responders, that do not improve and possibly worsen due to the persistence of sub-retinal fluid (with or without intra-retinal fluid) with chronic treatment. The investigators plan to evaluate the effect of oral doxycycline versus placebo on the anatomic and functional outcomes in persistent sub-retinal eye fluid in neovascular wet age-related macular degeneration. This subset are incomplete or non-responders to current anti-VEGF intravitreal therapy.

NCT ID: NCT03803631 Active, not recruiting - AMD Clinical Trials

CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)

COCTAEyl
Start date: April 4, 2018
Phase:
Study type: Observational

The main objective of this study is to analyze a new noninvasive imaging examination, OCT angiography, in the evaluation of neovascular remodeling and early signs of recurrence of wet AMD undergoing treatment on OCTA and to correlate OCTA findings with SD-OCT findings.

NCT ID: NCT02287298 Completed - Clinical trials for Exudative Macular Degeneration

Triple Combination Therapy of Choroidal Neovascularization in AMD, a Cost Effect and Efficient Therapeutic Treatment

Start date: August 2014
Phase: N/A
Study type: Observational

We propose to undertake a retrospective review of approximately 200 patients with a diagnosis of exudative macular degeneration treated with triple combination therapy (Bevacizumab, Dexamethasone and Photo-dynamic therapy) during the years of 2006 to 2010 at The Retina Center and compare those results with an additional group of approximately 200 patients also treated with triple combination therapy and 20 mg of daily oral zeaxanthin.

NCT ID: NCT01835067 Completed - Clinical trials for Exudative Macular Degeneration

Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD

TAPAS
Start date: September 2014
Phase: Phase 2/Phase 3
Study type: Interventional

This study will recruit patients who have recently had a submacular haemorrhage (bleed under the part of the retina responsible for detailed vision), as a complication of wet age-related macular degeneration (wet AMD). Wet AMD is a very common disease where abnormal blood vessels form under the retina and leak, causing a significant reduction in vision. The study will investigate treatment of the bleed with various combinations of the two drugs: tissue plasminogen activator (tPA) - designed to dissolve the blood clot; and perfluoropropane (C3F8) - designed to shift the blood clot away from the central part of the retina (the macula). tPA is a commonly used 'clot-buster' drug for the treatment of stroke. C3F8 is a gas commonly used in eye surgery. Patients recruited will be divided into four groups: control group that receive none of the above drugs; one group that receives only tPA; one group that receives only C3F8; and one group that receives both. All patients will receive the current gold standard treatment for wet AMD, ranibizumab (Lucentis®). The aim of the study is to improve vision in a condition, which left untreated, would cause severe visual loss.

NCT ID: NCT01674569 Completed - Clinical trials for Exudative Macular Degeneration

Pilot Study of X-82 in Patients With Wet AMD

Start date: October 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study is to evaluate the safety and preliminary biologic activity/efficacy of X-82 in patients with wet Age-related Macular Degeneration (AMD). Preliminary efficacy will be assessed by change from baseline in visual acuity, fluorescein leakage, retinal thickness and fibrosis, if detectable, based on fundus examination, fundus photography, fluorescein angiography and optical coherence tomography (OCT).

NCT ID: NCT01617148 Completed - Clinical trials for Exudative Macular Degeneration

Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept

Start date: June 2012
Phase: Phase 4
Study type: Interventional

This study will examine the use of Aflibercept in patients with exudative macular degeneration requiring intravitreal injections. Patients will be followed for 24 months. The follow up phase will be completed at month 36.

NCT ID: NCT01535950 Completed - Clinical trials for Exudative Macular Degeneration

Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)

Start date: February 2012
Phase: Phase 2
Study type: Interventional

This study will assess the safety and efficacy of LFG316 in patients with age related macular degeneration.

NCT ID: NCT01473251 Completed - Clinical trials for Diabetic Macular Edema

Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration

Start date: November 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to measure biomarkers in the vitreous of patients undergoing Lucentis or avastin treatment.